FUSN
Income statement / Annual
Last year (2023), Fusion Pharmaceuticals Inc.'s total revenue was $2.07 M,
an increase of 41.55% from the previous year.
In 2023, Fusion Pharmaceuticals Inc.'s net income was -$94.90 M.
See Fusion Pharmaceuticals Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$2.07 M |
$1.46 M |
$1.44 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$1.35 M
|
$58.90 M
|
$56.36 M
|
$482.00 K
|
$290.00 K
|
$0.00
|
$0.00
|
| Gross Profit |
$723.00 K
|
-$57.43 M
|
-$54.92 M
|
-$482.00 K
|
-$290.00 K
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.35
|
-39.31
|
-38.14
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$68.76 M
|
$58.90 M
|
$56.36 M
|
$17.19 M
|
$10.63 M
|
$6.88 M
|
$5.37 M
|
| General & Administrative Expenses |
$31.20 M
|
$30.60 M
|
$27.10 M
|
$20.74 M
|
$7.59 M
|
$3.22 M
|
$1.62 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$31.20 M
|
$30.60 M
|
$27.10 M
|
$20.74 M
|
$7.59 M
|
$3.22 M
|
$1.62 M
|
| Other Expenses |
$762.00 K
|
-$1.78 M
|
$469.00 K
|
-$31.72 M
|
-$176.00 K
|
-$1.71 M
|
$0.00
|
| Operating Expenses |
$99.96 M
|
$89.50 M
|
$83.46 M
|
$37.94 M
|
$18.04 M
|
$9.76 M
|
$6.99 M
|
| Cost And Expenses |
$101.30 M
|
$89.50 M
|
$83.46 M
|
$37.94 M
|
$18.04 M
|
$9.76 M
|
$6.99 M
|
| Interest Income |
$9.53 M
|
$2.16 M
|
$381.00 K
|
$327.00 K
|
$576.00 K
|
$0.00
|
$0.00
|
| Interest Expense |
$5.17 M
|
$1.80 M
|
$0.00
|
$327.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.35 M
|
$386.00 K
|
$634.00 K
|
$6.88 M
|
$466.00 K
|
$114.00 K
|
$23.00 K
|
| EBITDA |
-$87.60 M |
-$87.26 M |
-$81.38 M |
-$31.05 M |
-$17.75 M |
-$9.65 M |
-$6.96 M |
| EBITDA Ratio |
-42.36
|
-59.73
|
-56.51
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-47.98
|
-60.26
|
-56.95
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$5.12 M
|
-$1.42 M
|
$850.00 K
|
-$37.79 M
|
$2.28 M
|
-$1.71 M
|
$722.00 K
|
| Income Before Tax |
-$94.11 M
|
-$89.45 M
|
-$81.17 M
|
-$75.72 M
|
-$15.94 M
|
-$11.47 M
|
-$6.26 M
|
| Income Before Tax Ratio |
-45.51
|
-61.22
|
-56.36
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$787.00 K
|
-$1.84 M
|
-$118.00 K
|
$2.61 M
|
$251.00 K
|
$181.00 K
|
$0.00
|
| Net Income |
-$94.90 M
|
-$87.61 M
|
-$81.05 M
|
-$78.33 M
|
-$16.19 M
|
-$11.65 M
|
-$6.26 M
|
| Net Income Ratio |
-45.89
|
-59.97
|
-56.28
|
0
|
0
|
0
|
0
|
| EPS |
-1.45 |
-2 |
-1.9 |
-3.56 |
-0.1 |
-0.62 |
-0.34 |
| EPS Diluted |
-1.45 |
-2 |
-1.9 |
-3.56 |
-0.1 |
-0.62 |
-0.34 |
| Weighted Average Shares Out |
$65.61 M
|
$43.75 M
|
$42.60 M
|
$22.03 M
|
$155.71 M
|
$18.70 M
|
$18.70 M
|
| Weighted Average Shares Out Diluted |
$65.61 M
|
$43.75 M
|
$42.60 M
|
$22.03 M
|
$155.71 M
|
$18.70 M
|
$18.70 M
|
| Link |
|
|
|
|
|
|
|
